{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:09:46Z","timestamp":1789441786798,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40271-018-0319-3","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T21:54:57Z","timestamp":1529358897000},"page":"527-537","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Patient Perspective on Acute Intermittent Porphyria with Frequent Attacks: A Disease with Intermittent and Chronic Manifestations"],"prefix":"10.1007","volume":"11","author":[{"given":"Amy","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrah","family":"Pompilus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Querbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Strzok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Penz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desiree Lyon","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Hungate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonalee","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Marquis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,19]]},"reference":[{"issue":"9718","key":"319_CR1","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(09)61925-5","volume":"375","author":"H Puy","year":"2010","unstructured":"Puy H, Gouya L, Deybach JC. Porphyrias. Lancet. 2010;375(9718):924\u201337.","journal-title":"Lancet."},{"issue":"6","key":"319_CR2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.7326\/0003-4819-142-6-200503150-00010","volume":"142","author":"KE Anderson","year":"2005","unstructured":"Anderson KE, Bloomer JR, Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med. 2005;142(6):439\u201350.","journal-title":"Ann Intern Med."},{"issue":"23","key":"319_CR3","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1182\/blood-2012-05-423186","volume":"120","author":"M Balwani","year":"2012","unstructured":"Balwani M, Desnick RJ. The porphyrias: advances in diagnosis and treatment. Blood. 2012;120(23):4496\u2013504.","journal-title":"Blood."},{"key":"319_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/TACG.S48605","volume":"8","author":"E Pischik","year":"2015","unstructured":"Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. Appl Clin Genet. 2015;8:201\u201314.","journal-title":"Appl Clin Genet."},{"issue":"12","key":"319_CR5","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.amjmed.2014.06.036","volume":"127","author":"HL Bonkovsky","year":"2014","unstructured":"Bonkovsky HL, Maddukuri VC, Yazici C, Anderson KE, Bissell DM, Bloomer JR, et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med. 2014;127(12):1233\u201341.","journal-title":"Am J Med."},{"issue":"Pt 3","key":"319_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1177\/0004563212474555","volume":"50","author":"P Stein","year":"2013","unstructured":"Stein P, Badminton M, Barth J, Rees D, Stewart MF, et al. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. Ann Clin Biochem. 2013;50(Pt 3):217\u201323.","journal-title":"Ann Clin Biochem."},{"issue":"4","key":"319_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/(SICI)1096-8628(19961111)65:4<269::AID-AJMG4>3.0.CO;2-K","volume":"65","author":"JB Jeans","year":"1996","unstructured":"Jeans JB, Savik K, Gross CR, Weimer MK, Bossenmaier IC, Pierach CA, et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: a United States case series. Am J Med Genet. 1996;65(4):269\u201373.","journal-title":"Am J Med Genet."},{"issue":"5","key":"319_CR8","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s10545-012-9544-4","volume":"36","author":"G Elder","year":"2013","unstructured":"Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The incidence of inherited porphyrias in Europe. J Inherit Metab Dis. 2013;36(5):849\u201357.","journal-title":"J Inherit Metab Dis."},{"issue":"3","key":"319_CR9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ymgme.2016.08.006","volume":"119","author":"H Naik","year":"2016","unstructured":"Naik H, Stoecker M, Sanderson SC, Balwani M, Desnick RJ. Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: a qualitative study. Mol Genet Metab. 2016;119(3):278\u201383.","journal-title":"Mol Genet Metab."},{"issue":"7","key":"319_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1023\/A:1012901607040","volume":"24","author":"LM Millward","year":"2001","unstructured":"Millward LM, Kelly P, Deacon A, Senior V, Peters TJ. Self-rated psychosocial consequences and quality of life in the acute porphyrias. J Inherit Metab Dis. 2001;24(7):733\u201347.","journal-title":"J Inherit Metab Dis."},{"issue":"2","key":"319_CR11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1046\/j.1365-2796.2003.01172.x","volume":"254","author":"C Andersson","year":"2003","unstructured":"Andersson C, Innala E, Backstrom T. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones: a population-based study in northern Sweden. J Intern Med. 2003;254(2):176\u201383.","journal-title":"J Intern Med."},{"key":"319_CR12","unstructured":"Gouya L. EXPLORE: a prospective, multinational natural history study of acute hepatic porphyria patients with recurrent attacks. International Liver Congress, Paris, 11\u201315 Apr 2018."},{"key":"319_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/8904_2015_411","volume":"22","author":"JT Marsden","year":"2015","unstructured":"Marsden JT, Guppy S, Stein P, Cox TM, Badminton M, Gardiner T, et al. Audit of the use of regular haem arginate infusions in patients with acute porphyria to prevent recurrent symptoms. JIMD Rep. 2015;22:57\u201365.","journal-title":"JIMD Rep."},{"issue":"6","key":"319_CR14","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s10545-005-4561-1","volume":"28","author":"LM Millward","year":"2005","unstructured":"Millward LM, Kelly P, King A, Peters TJ. Anxiety and depression in the acute porphyrias. J Inherit Metab Dis. 2005;28(6):1099\u2013107.","journal-title":"J Inherit Metab Dis."},{"issue":"30","key":"319_CR15","doi-asserted-by":"publisher","first-page":"e1023","DOI":"10.1097\/MD.0000000000001023","volume":"94","author":"AM Jimenez-Monreal","year":"2015","unstructured":"Jimenez-Monreal AM, Murcia MA, Gomez-Murcia V, Bibiloni Mdel M, Pons A, Tur JA, et al. Anthropometric and quality-of-life parameters in acute intermittent porphyria patients. Medicine (Baltimore). 2015;94(30):e1023.","journal-title":"Medicine (Baltimore)."},{"issue":"6","key":"319_CR16","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1046\/j.1365-2648.2000.01628.x","volume":"32","author":"A Wikberg","year":"2000","unstructured":"Wikberg A, Jansson L, Lithner F. Women\u2019s experience of suffering repeated severe attacks of acute intermittent porphyria. J Adv Nurs. 2000;32(6):1348\u201355.","journal-title":"J Adv Nurs."},{"issue":"6999","key":"319_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1136\/bmj.311.6999.251","volume":"311","author":"N Britten","year":"1995","unstructured":"Britten N. Qualitative interviews in medical research. BMJ. 1995;311(6999):251\u20133.","journal-title":"BMJ."},{"key":"319_CR18","unstructured":"US Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labelling claims. 2009. \n                    https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm193282.pdf\n                    \n                  . Accessed 7 Jun 2018."},{"key":"319_CR19","unstructured":"US Food and Drug Administration. Roadmap to patient-focused outcome measurement in clinical trials. 2013. \n                    https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/DrugDevelopmentToolsQualificationProgram\/ucm370177.htm\n                    \n                  . Accessed 7 Jun 2018."},{"issue":"2","key":"319_CR20","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/1098214005283748","volume":"27","author":"DR Thomas","year":"2006","unstructured":"Thomas DR. A general inductive approach for analyzing qualitative evaluation data. Am J Eval. 2006;27(2):237\u201346.","journal-title":"Am J Eval."},{"key":"319_CR21","doi-asserted-by":"publisher","DOI":"10.4324\/9780203413081","volume-title":"Analyzing qualitative data","author":"A Bryman","year":"2002","unstructured":"Bryman A, Burgess B. Analyzing qualitative data. New York: Routledge; 2002."},{"key":"319_CR22","doi-asserted-by":"publisher","DOI":"10.17169\/fqs-11.3.1428","author":"M Mason","year":"2010","unstructured":"Mason M. Sample size and saturation in PhD studies using qualitative interviews. Forum Qual Soc Sci Res. 2010. \n                    https:\/\/doi.org\/10.17169\/fqs-11.3.1428","journal-title":"Forum Qual Soc Sci Res"},{"issue":"9","key":"319_CR23","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s11136-009-9540-9","volume":"18","author":"M Brod","year":"2009","unstructured":"Brod M, Tesler LE, Christensen TL. Qualitative research and content validity: developing best practices based on science and experience. Qual Life Res. 2009;18(9):1263\u201378.","journal-title":"Qual Life Res."},{"key":"319_CR24","unstructured":"American Porphyria Foundation. The voice of the patient: patient-focused drug development meeting. Acute porphyrias. 2017. \n                    http:\/\/www.porphyriafoundation.com\/sites\/default\/files\/APFPFDDMeetingMarch1%2C2017-TheVoiceofthePatient%20%281%29.pdf\n                    \n                  . Accessed 7 Jun 2018."},{"issue":"5","key":"319_CR25","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1080\/00365510902935979","volume":"69","author":"I Bylesjo","year":"2009","unstructured":"Bylesjo I, Wikberg A, Andersson C. Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. Scand J Clin Lab Invest. 2009;69(5):612\u20138.","journal-title":"Scand J Clin Lab Invest."},{"key":"319_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12955-018-0851-9","volume":"16","author":"ME Hyland","year":"2018","unstructured":"Hyland ME, Lanario JW, Pooler J, Masoli M, Jones RC. How patient participation was used to develop a questionnaire that is fit for purpose for assessing quality of life in severe asthma. Health Qual Life Outcomes. 2018;16:24.","journal-title":"Health Qual Life Outcomes."},{"key":"319_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2288-11-26","volume":"11","author":"B Carlsen","year":"2011","unstructured":"Carlsen B, Glenton C. What about N? A methodological study of sample-size reporting in focus group studies. BMC Med Res Methodol. 2011;11:26. \n                    https:\/\/doi.org\/10.1186\/1471-2288-11-26\n                    \n                  .","journal-title":"BMC Med Res Methodol."}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40271-018-0319-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-018-0319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-018-0319-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T16:40:17Z","timestamp":1568997617000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40271-018-0319-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1007\/s40271-018-0319-3","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,19]]},"assertion":[{"value":"19 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by Alnylam Pharmaceuticals, Cambridge, MA, USA. Data collection and analysis were performed by Modus Outcomes under the direction of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Amy Simon, William Querbes, Alex Wei, Craig Penz, Jae B. Kim, and Sonalee Agarwal are employees of Alnylam Pharmaceuticals, which sponsored this study. Farrah Pompilus, Sara Strzok, and Patrick Marquis are employees of Modus Outcomes and received funding from Alnylam Pharmaceuticals to conduct the study. Desiree Lyon Howe and Jessica R. Hungate are employees of the American Porphyria Foundation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The data that support the findings of this study may be available on request from the corresponding author (AS), based on the specific request. The data are not publicly available because they contain information that could compromise research participant privacy\/consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}}]}}